BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19273341)

  • 1. The dual function of the MHC class II transactivator CIITA against HTLV retroviruses.
    Tosi G; Bozzo L; Accolla RS
    Front Biosci (Landmark Ed); 2009 Jan; 14(11):4149-56. PubMed ID: 19273341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators.
    Forlani G; Abdallah R; Accolla RS; Tosi G
    Front Microbiol; 2013; 4():234. PubMed ID: 23986750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.
    Tosi G; Forlani G; Andresen V; Turci M; Bertazzoni U; Franchini G; Poli G; Accolla RS
    J Virol; 2011 Oct; 85(20):10719-29. PubMed ID: 21813598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.
    Forlani G; Abdallah R; Accolla RS; Tosi G
    J Virol; 2016 Jan; 90(7):3708-21. PubMed ID: 26792751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2.
    Casoli C; De Lerma Barbaro A; Pilotti E; Bertazzoni U; Tosi G; Accolla RS
    Blood; 2004 Feb; 103(3):995-1001. PubMed ID: 14525769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.
    Forlani G; Shallak M; Ramia E; Tedeschi A; Accolla RS
    Retrovirology; 2019 Nov; 16(1):34. PubMed ID: 31783769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.
    Tosi G; Pilotti E; Mortara L; De Lerma Barbaro A; Casoli C; Accolla RS
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12861-6. PubMed ID: 16908858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication.
    Orlandi C; Forlani G; Tosi G; Accolla RS
    J Transl Med; 2011 Jul; 9():106. PubMed ID: 21736733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
    Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
    Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
    Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
    J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
    Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
    J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes--class II MHC, Ii and H-2M. Class II TransActivator.
    Kielar ML; Sicher SC; Penfield JG; Jeyarajah DR; Lu CY
    Inflammation; 2000 Oct; 24(5):431-45. PubMed ID: 10921507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes.
    Bissa M; Forlani G; Zanotto C; Tosi G; De Giuli Morghen C; Accolla RS; Radaelli A
    PLoS One; 2018; 13(1):e0190869. PubMed ID: 29385169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
    Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
    J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
    Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
    J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status.
    Hara H; Witt W; Crossley T; Long C; Isse K; Fan L; Phelps CJ; Ayares D; Cooper DK; Dai Y; Starzl TE
    Immunology; 2013 Sep; 140(1):39-46. PubMed ID: 23566228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
    Accolla RS; Ramia E; Tedeschi A; Forlani G
    Front Immunol; 2019; 10():1806. PubMed ID: 31417570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
    Broxmeyer HE; Cooper S; Hangoc G; Chang CH
    Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.
    Forlani G; Turrini F; Ghezzi S; Tedeschi A; Poli G; Accolla RS; Tosi G
    J Transl Med; 2016 Apr; 14():94. PubMed ID: 27089879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.